Lung Cancer Screening Market Size, Share, Growth, Trends, and Global Industry Analysis: By Cancer Type (Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer), By Diagnosis Type (Low Dose Spiral CT scan, And Chest X-Ray), By End-Users (Hospital & Clinics and Diagnostic Centers) and Region Forecast 2019-2030

Lung Cancer Screening Market size was valued at US$ 2,862.1 million in 2023 and is poised to grow at a significant CAGR of 6.5% from 2024-2030. A type of disease that occurs in the lungs is known as lung cancer. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the 2 main types of lung cancer and are treated differently. The non-small cell lung cancer segment is anticipated to grow at a significant CAGR over the forecast years owing to non-small cell lung cancer being the most common type of cancer accounting for approximately 85% of all lung cancers.

However, non-small cell Lung cancer metastasizes to another organ slower in compression to SCLC, and microscopically, SCLC is composed of much smaller cells. if untreated, SCLC can be fatal in a few weeks, in contrast to most cases of NSCLC. Moreover, as per the research, non-small cell lung cancer accounts for 85% of all lung cancer cases in the United States after the initial diagnosis. The prevalence of lung cancer cases worldwide, greater emphasis on technological developments in the production of medical devices, and rising spending on the expansion of healthcare infrastructure, particularly in developing economies, are the main drivers of the market.

Key Developments

• In November 2023, Thirona, Incepto, and Aidence jointly introduced a clinical solution to help lung cancer screening spread throughout Europe. This cooperative initiative represents a calculated step to improve screening capacities and help identify and treat lung cancer more effectively throughout the continent.
• In November 2023, Thynk Health and Infervision established a strategic partnership that will use the most cutting-edge technology available to fight lung cancer. Through this partnership, Thynk Health is positioned as a major participant in pulmonary nodule management and cutting-edge healthcare solutions, in addition to facilitating enhanced lung cancer detection.